Here we wanted to test the concept that a combined PPARα/γ agonist could improve metabolic flexibility in a widely used animal model of insulin resistance and dyslipidemia associated with obesity, the fa/fa Zucker rat. Here, PPARA is linked to metabolic syndrome.